Biotie Therapies - Financial Calendar

Change in Biotie Therapies' Financial Calendar 2015

BIOTIE THERAPIES CORP.                        Stock Exchange
Release                     23 April 2015 at 10.18 am

Change in Biotie Therapies' Financial Calendar 2015

Biotie Therapies Corp. ("Biotie") will now publish its Interim Financial Report
for January to March 2015 on 6 May 2015; the previously announced date was 29
April 2015.

Turku, 23 April 2015

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:
Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

www.biotie.com

DISTRIBUTION:
NASDAQ OMX Helsinki Ltd
Main Media

About Biotie

Biotie is a specialized drug development company focused on products for
neurodegenerative and psychiatric disorders. Biotie's development has delivered
Selincro (nalmefene) for alcohol dependence, which received European marketing
authorization in 2013 and is currently being rolled out across Europe by partner
Lundbeck. The current development products include tozadenant for Parkinson's
disease, which is transitioning into Phase 3 development, and two additional
compounds which are in Phase 2 development for cognitive disorders including
Parkinson's disease dementia, and primary sclerosing cholangitis (PSC), a rare
fibrotic disease of the liver.




[HUG#1913795]